ChrysCapital acquires a 70.68% stake in Novartis India in a ₹1,446 crore deal, appoints new leadership and targets growth in branded generics.

ChrysCapital acquires a 70.68% stake in Novartis India in a ₹1,446 crore deal, appoints new leadership and targets growth in branded generics.

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition,…